X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Study results show that treatment with Golexanolone (GR3027) for 7 days significantly reduced fatigue in test group compared to the control group (p<0.05). Further analysis shows that treatment also improved other CNS symptoms.
Lead Product(s): Golexanolone
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: GR3027
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2022
Details:
Results from previous clinical and pre-clinical studies strongly indicate that GR3027 (golexanolone) is able to counteract such inappropriate suppression of brain activity.
Lead Product(s): Golexanolone
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: GR3027
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2022
Details:
Golexanolone, a novel drug candidate that counter acts the effect of allopregnanolone on GABAA receptors, thereby restoring normal nerve signalling in the brain.
Lead Product(s): Golexanolone
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: GR3027
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2021
Details:
Umecrine Cognition will present the results from its recently conducted clinical phase 2a study of the drug candidate golexanonole, that is in clinical development for hepatic encephalopathy.
Lead Product(s): Golexanolone
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: GR3027
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2020
Details:
Analyses of data for additional efficacy endpoints reveal that treatment with the golexanolone exerts a significant effect on brain signaling with a positive effect on excessive daytime sleepiness.
Lead Product(s): Golexanolone
Therapeutic Area: Sleep Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2020
Details:
Results demonstrate a positive safety and tolerability profile; however, no indications of clinical effects could be observed.
Lead Product(s): Golexanolone
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
